drugset / Trial / NCT07365410
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effective and safer.
Timeline
- Start
- 2026-01
- Primary completion
- 2026-05
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Firmonertinib | Small molecule | 80 mg | Oral |
| Comparator | Firmonertinib | Small molecule | 160 mg | Oral |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Pemetrexed | Small molecule | — | Intravenous |